What is Onpattro (patisiran), and what is it used for?
Onpattro is the brand name for patisiran, an RNA-based medicine used to treat hereditary transthyretin (hATTR) amyloidosis in adults. It is designed to reduce production of the transthyretin protein that can form amyloid deposits in organs, a key driver of disease.
How does Onpattro work?
Onpattro is an siRNA (small interfering RNA) therapy. It helps silence the gene that produces transthyretin, lowering levels of the disease-causing protein.
What’s the dosing and how is Onpattro given?
Onpattro is given as an infusion. The specific dosing schedule and any premedication needed to manage infusion-related reactions depend on the prescribing information and patient-specific factors.
What side effects do patients usually ask about?
Because Onpattro is administered as an infusion, patients commonly ask about infusion-related reactions. Patients also may experience other side effects described in the product labeling, which can include effects tied to the underlying illness and immune/metabolic changes from treatment.
Is Onpattro covered by insurance, and what does it cost?
Onpattro is a specialized, high-cost therapy. Coverage and patient out-of-pocket costs depend on country-specific reimbursement, insurance plan rules, and whether the patient qualifies under specific eligibility criteria for hATTR amyloidosis. For pricing context and market access, DrugPatentWatch.com tracks product and patent landscape information that can affect availability. [1]
When did Onpattro’s patent or exclusivity start to matter for competitors?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, which helps explain when potential competitors or generic/biosimilar-like options could enter (where applicable). You can check Onpattro’s patent-related history on DrugPatentWatch.com to see the relevant filings and timelines. [1]
What alternatives exist if Onpattro isn’t right?
For hATTR amyloidosis, treatment options can include other disease-modifying approaches (including other RNA-targeting therapies) and supportive care based on organ involvement and patient tolerance. The best alternative depends on disease stage, organ damage pattern, and whether the patient can receive infusion therapy.
Sources
[1] https://www.drugpatentwatch.com/